Ascites in infantile onset type II Sialidosis

Sialidosis is a rare autosomal‐recessive lysosomal storage disease due to mutations in the NEU1 gene leading to a deficit of alpha‐n‐acetyl neuraminidase and causing aberrant accumulation of sialylated glycoproteins/peptides and oligosaccharides in the lysosomes of various organs and tissues. Type II sialidosis (dysmorphic form) is classified into three subgroups based on the age of onset and the clinical severity: Congenital or neonatal, infantile (onset 0–12 months) and juvenile form (onset 13 months–20 years). We report the case of a 3‐year‐old boy with sialidosis type II infantile form, who developed a voluminous ascites. To the best of our knowledge, ascites is not described in the infantile form but in the congenital form of the disease. Ascites seems to be of a multifactorial origin regarding our investigations: on the one hand, portal hypertension and on the other hypoalbuminemia maintained by proteinuria secondary to nephrosialidosis. Loss of plasma proteins in the gastrointestinal tract (protein‐losing enteropathy) should also be considered in the case of portal hypertension and damages of the reticuloendothelial system.

[1]  W. Hwu,et al.  Throwing a spotlight on under-recognized manifestations of Gaucher disease: Pulmonary involvement, lymphadenopathy and Gaucheroma. , 2021, Molecular genetics and metabolism.

[2]  P. Tanpowpong,et al.  Gastrointestinal protein loss in children with portal hypertension , 2020, Indian Journal of Gastroenterology.

[3]  M. Schmidts,et al.  Parental Whole-Exome Sequencing Enables Sialidosis Type II Diagnosis due to an NEU1 Missense Mutation as an Underlying Cause of Nephrotic Syndrome in the Child , 2018, Kidney international reports.

[4]  C. Sergi,et al.  Sialidosis: A Review of Morphology and Molecular Biology of a Rare Pediatric Disorder , 2018, Diagnostics.

[5]  Farzana Perwad,et al.  Monogenic Causes of Proteinuria in Children , 2018, Front. Med..

[6]  David G Levitt,et al.  Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states , 2017, Clinical and experimental gastroenterology.

[7]  Ida Annunziata,et al.  Pathogenesis, emerging therapeutic targets and treatment in sialidosis , 2015, Expert opinion on orphan drugs.

[8]  R. Penzel,et al.  Prenatal diagnosis and fetal pathology in a Turkish family harboring a novel nonsense mutation in the lysosomal α-N-acetyl-neuraminidase (sialidase) gene , 2001, Human Genetics.

[9]  A. Russo,et al.  Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF) - more common than assumed? Report of four cases with transient NIHF and a review of the literature , 2012, Orphanet Journal of Rare Diseases.

[10]  S. Macedo-Ribeiro,et al.  Lysosomal multienzymatic complex‐related diseases: a genetic study among Portuguese patients , 2012, Clinical genetics.

[11]  R. Bandyopadhyay,et al.  Gauchers disease presenting with portal hypertension. , 2011, Indian pediatrics.

[12]  K. Dolman,et al.  Clinical practice , 2010, European Journal of Pediatrics.

[13]  K. Dolman,et al.  Clinical practice-Protein-losing enteropathy in children , 2010 .

[14]  S. Grossi,et al.  Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients , 2009, Journal of Neurology.

[15]  Ellen Sidransky,et al.  Lysosomal Storage Disorders in the Newborn , 2009, Pediatrics.

[16]  David J. Loren,et al.  Sialidosis Presenting as Severe Nonimmune Fetal Hydrops is Associated with Two Novel Mutations in Lysosomal α-Neuraminidase , 2005, Journal of Perinatology.

[17]  P. Angus,et al.  Modern management of portal hypertension , 2005, Internal medicine journal.

[18]  A. Pshezhetsky,et al.  Clinical variability of type II sialidosis by C808T mutation , 2003, American journal of medical genetics. Part A.

[19]  W. Arts,et al.  Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. , 2000, Human molecular genetics.

[20]  D. Lomas,et al.  Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features. , 2000, QJM : monthly journal of the Association of Physicians.

[21]  M. Fornerod,et al.  Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. , 1996, Genes & development.

[22]  V. Yu,et al.  Nonimmunologic Hydrops Fetalis: A Review of 61 Cases , 1982, Obstetrics and gynecology.

[23]  J. O'brien,et al.  Sialidosis: a review of human neuraminidase deficiency. , 1979, American journal of human genetics.

[24]  M. Kew,et al.  Gaucher's disease with portal hypertension: case report. , 1966, The Journal of pediatrics.

[25]  M. Lane,et al.  Gaucher's disease with ascites: a case report with autopsy findings. , 1955, Annals of internal medicine.